Canadian taxpayers are still being compelled to pay $350 million to Novavax Inc. for a number of shots that were never even delivered, let alone disseminated, even though Canada subsequently found that it did not require nearly as many Wuhan coronavirus (COVID-19) “vaccines” as it had initially believed.
The Canadian public works and government services department and Novavax, a US-based company that was excluded from this country’s COVID vaccine rollout, reportedly reached an agreement to modify the advance purchase contract after it became apparent that significantly fewer people than expected were waiting in line for COVID vaccinations.
In other words, Novavax produced far more injectable vials than were required. The pharmaceutical behemoth is requesting compensation for medicines that were never used, rather than bearing the expense like businesses in other sectors do.
According to the corporation, fewer jab doses are now scheduled for delivery, and the remaining doses’ shipping dates have been adjusted in accordance with the modified terms.
Without this massive cash infusion from Canadian taxpayers, Novavax faces imminent bankruptcy and collapse
The $350 million payment will reportedly be sent to Novavax in two equal installments in 2023, despite the fact that the contract’s initial value remains the same.
If the corporation is unable to obtain regulatory permission for the production of vaccines at the Biologics Manufacturing Centre by December 31, 2024, the Canadian government may still be able to terminate its contract with the company.
“Novovax – which has its COVID-19 vaccine as the only marketed product after 35 years in business – has raised doubts about its ability to remain in business, flagging uncertainties around its revenue and funding crunch,” Reuters reported about the matter.
“The company said in May it expects 2023 revenue between $1.4 billion and $1.6 billion, of which $800 million was from ‘locked-in’ overseas purchase contracts for the COVID shot that it has committed to ship this year.”
To put it another way, if Canadian taxpayers were not being forced to foot the bill for Novavax’s excessive non-delivery of unnecessary COVID shots, the company would soon go out of business and collapse.
In fact, the corporation stated that if the capital infusion is not done, it might not even last through the end of 2023.
Through a 2021 agreement, Canada approved both the initial series and booster of the recombinant protein vaccine Nuvaxovid developed by Novavax. As previously noted, preparations are being made to manufacture the injection right here in Canada at the Biologics Manufacturing Centre (BMC) of the National Research Council of Canada in Montreal.
Novavax claims that in order to strengthen its ties to the Canadian market, it will “provide health, economic, and future pandemic preparedness benefits to Canada,” which may include the signing of a 15-year memorandum of understanding that would be worth at least as much as what Canada intends to pay Novavax for its ongoing COVID jab orders.
There are reportedly many COVID shots that are left over with nowhere to go but the trash because no one wants to get injected for the disease anymore. This is also true with AstraZeneca’s COVID vaccines, 13.6 million doses of which are slated for disposal in Canada.
Covifenz, a less popular “plant-based” COVID injection, is also performing poorly, pushing its Canadian maker, Medicago, into bankruptcy this year. As it turned out, Medicago was unable to find a market for its COVID vaccine, especially once it became apparent that the “pandemic” was essentially a fraud.
SOURCES: REUTERS, FIERCE PHARMA
You must be logged in to post a comment Login